香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 收購美國物業及設立美國附屬公司ETHK BANK 於美國推進穩定幣及知識產權證券化新征程 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 已 於 近 期 完 成 收 購 位 於 美 國 加 利 福 尼 亞 州 奧 蘭 治 縣 爾 灣 市 一 處 物 業（「該物業」），總 代 價 為436.5萬 美 元。同 時， 本公司於美國科羅拉多州註冊成立全資附屬公 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華檢醫療控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01931 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | 本月底法定/註 ...

Major Events - Jinye International Group (08549) plans to issue 100 million shares from September 30 to October 6 [1] - Zhida Technology (02650) intends to globally issue 5.9789 million shares, expecting to list on October 10 [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2070 injection (double-stranded small interfering RNA drug) in China [1] - Mixue Group (02097) plans to invest in a fresh beer product company to seize opportunities in the fresh beer industry [1] - Shangshan Gold (01939) proposes a placement at a discount of approximately 19.88%, aiming to raise about HKD 245.8 million [1] - GC Construction (01489) sees a change in controlling interest with a buyout offer at a discount of about 45.91%, resuming trading on October 2 [1] - Times Financial Services Group (00510) major shareholder plans to sell some shares, resuming trading on October 2 [1] - Huajian Medical (01931) confidentially submitted an F-1 registration statement for a dual listing in the U.S. [1] - Ding Shi Capital (00804) intends to acquire 100% equity of a distressed asset disposal business, actively entering the distressed asset market [1] - Chuangmeng Tiandi (01119) plans to issue a total of 236 million shares [1] - Zhaogang Group-W (06676) intends to conduct a share buyback [1] - Daren International (01957) is exploring the possibility of acquiring up to 100 bitcoins [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed L-carnosine composite solution water light needle "Frozen Beauty" [1] Bonds and Notes - Minmetals Resources (01208) plans to issue USD 500 million zero-coupon convertible bonds maturing in 2030 [2] Share Buybacks - Tencent Holdings (00700) repurchased approximately 832,000 shares for about HKD 551 million on September 30 [2] - Midea Group (00300) spent approximately CNY 146 million to repurchase 2.0015 million A-shares on September 30 [2] - Anta Sports (02020) repurchased approximately 1.000 million shares for about HKD 99.87 million on September 30 [2] - SF Holding (06936) repurchased approximately 937,600 A-shares for about CNY 37.78 million on September 30 [2] - HSBC Holdings (00005) repurchased approximately 2.1133 million shares for about GBP 22.07 million on September 29 [2] Operating Performance - BYD Company (01211) reported approximately 3.2601 million new energy vehicle sales in the first nine months, a year-on-year increase of 18.64% [2] - Geely Automobile (00175) reported total vehicle sales of 273,100 units in September, a year-on-year increase of approximately 35% [2] - Great Wall Motors (02333) reported total vehicle sales of approximately 133,600 units in September, a year-on-year increase of 23.29% [2] - NIO Inc. (09866) delivered 34,749 vehicles in September, setting a new monthly record with a year-on-year increase of 64.1% [2] - Li Auto (02015) delivered 33,951 new vehicles in September [2]

Core Viewpoint - The company has submitted a confidential F-1 registration statement to the U.S. Securities and Exchange Commission for a proposed dual listing in the U.S., which is a significant step in its global strategy and is expected to bring multiple positive impacts [1] Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1] - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1] Group 2: Brand and Market Presence - Listing on NASDAQ is expected to enhance the company's international brand influence, improving its corporate image and industry recognition in global markets [1] - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1] Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is likely to broaden the investor base and enhance overall share liquidity [1] - This international pricing environment is expected to better reflect the company's long-term value [1] Group 4: Governance and Compliance - Adhering to U.S. securities regulations and disclosure requirements is projected to improve the company's governance standards and operational transparency [1] - This will strengthen the company's compliance image and investor trust on a global scale [1] Group 5: Strategic Flexibility - The dual listing structure will provide the company with a richer platform for capital operations and strategic options for future international collaborations, mergers, and business expansions [1]

Core Viewpoint - The company has decided to pursue a dual primary listing on the NASDAQ stock market through an initial public offering of American Depositary Shares, which is a significant step in its global strategic layout, expected to bring multiple positive impacts. Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1]. - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1]. Group 2: Brand and Market Presence - Listing on NASDAQ will enhance the company's international brand influence, improving its corporate image and industry recognition in the global market [1]. - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1]. Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is expected to broaden the investor base and enhance overall share liquidity [1]. - This environment will allow the company's long-term value to be fully reflected in a more international pricing context [1]. Group 4: Governance and Transparency - Adhering to U.S. securities regulations and disclosure requirements will improve the company's governance standards and operational transparency [1]. - This compliance is likely to strengthen the company's global compliance image and investor trust [1]. Group 5: Strategic Flexibility - The dual listing structure will provide the company with greater flexibility for future international collaborations, mergers, and business expansions, offering a richer platform for capital operations and strategic choices [2].

Core Viewpoint - The company, Huajian Medical, has proposed a dual primary listing on the NASDAQ stock market through the issuance of new ordinary shares in the form of American Depositary Shares, with a confidential F-1 registration statement submitted to the SEC on September 29, 2025. This move is part of the company's global strategic layout and is expected to bring multiple positive impacts. Group 1: Strategic Impacts - Expanding global financing channels: Entering one of the largest and most comprehensive capital markets globally is expected to attract more long-term international investors focused on biotechnology and healthcare, providing strong capital support for future R&D and commercialization [1] - Enhancing international brand influence: Listing on NASDAQ will further enhance the company's corporate image and industry recognition in international markets, increasing opportunities for communication and collaboration with global partners, clients, and regulatory bodies [1] - Increasing share liquidity and valuation potential: Establishing a cross-market trading mechanism will help expand the investor base, improve overall share liquidity, and reflect the company's long-term value in a more international pricing environment [1] - Optimizing corporate governance and transparency: Adhering to U.S. securities regulations and disclosure requirements will enhance the company's governance standards and operational transparency, strengthening its compliance image and investor trust globally [1] Group 2: Future Strategic Flexibility - Providing flexibility for future strategic advancement: The dual listing structure offers a richer capital operation platform and strategic options for potential international cooperation, mergers, and business expansion [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責 任。 本 公 告 僅 作 參 考 用 途，並 不 構 成 在 香 港 或 任 何 其 他 地 方 收 購、購 買 或 認 購 任 何 證 券 的 任 何 邀 請 或 要 約，本 公 告（或 其 任 何 部 分）或 分 發 本 公 告 之 事 實 亦 不 會 構 成 任 何 認 購 證 券 合 約 或 邀 請 的 基 準 或 有 關 依 據，且 僅 供 說 明 用 途。分 發 本 公 告 可 能 在 若 干 司 法 管 轄 區 受 到 法 律 限 制，而 獲 得 本 公 告 所 述 資 料 的 人 士 應 自 行 了 解 及 遵 守 任 何 該 等 限 制。任 何 未 能 遵 守 此 等 限 制 之 情 況 可 能 構 成 任 何 有 關 司 法 管 轄 區 的 違 法 行 為。本 公 告 所 述 的 證 券 尚 未 根 據 任 何 證 券 法 律 及 規 ...

(Stock Code: 1931) NOTIFICATION LETTER 通知信函 30 September 2025 Dear Non-registered Holder(s) (Note 1) , IVD Medical Holding Limited (the "Company") － Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.ivdholding.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Versio ...

IVD Medical Holding Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.ivdholding.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Com ...

Financial Performance - The company reported revenue of RMB 1,269,595,000 for the six months ended June 30, 2025, a decrease of 6.2% compared to RMB 1,353,470,000 in the same period of 2024[10]. - Gross profit for the period was RMB 279,594,000, down 13.9% from RMB 324,692,000 year-on-year[10]. - Net profit for the period decreased by 70.0% to RMB 38,326,000, compared to RMB 127,566,000 in the previous year[10]. - Adjusted net profit (non-GAAP) was RMB 35,628,000, a decline of 72.1% from RMB 127,790,000 in the same period last year[11]. - The revenue from solution services provided to hospitals was RMB 108,899,000, a decrease of 7.3% compared to RMB 117,462,000 for the six months ending June 30, 2024, primarily due to reduced market demand[16]. - The group's total revenue for the six months ended June 30, 2025, was RMB 1,181,820,000, a decrease of 6.1% compared to RMB 1,258,212,000 for the same period in 2024[46]. - The net profit for the period was RMB 38,326,000, down RMB 89,240,000 or 70.0% year-on-year[26]. - Adjusted net profit decreased to RMB 35,628,000, a decline of RMB 92,162,000 or 72.1% compared to the previous year[26]. - The group's profit for the period was RMB 38,326,000, a decrease of 70.0% from RMB 127,566,000 for the six months ended June 30, 2024, attributed to reduced revenue, lower gross margin, increased administrative expenses, and higher selling and distribution expenses[62]. Market and Operational Insights - The company installed approximately 6,605 Sysmex coagulation analyzers in hospitals and medical institutions across China as of June 30, 2025[14]. - The company has been the exclusive distributor of Sysmex coagulation products in China for 27 years, strengthening its market position[15]. - The company continues to enhance its collaboration with Sysmex to adapt to the dynamic demands of the Chinese medical device market[15]. - The company aims to provide a competitive and diverse product portfolio to stabilize market share and profitability[13]. - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[19]. - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market, including establishing relationships with well-known IVD manufacturers[22]. Financial Position and Cash Flow - Total assets increased by 11.5% to RMB 6,159,137,000 from RMB 5,523,884,000[32]. - Cash and cash equivalents decreased significantly by 76.1% to RMB 424,849,000 from RMB 1,774,358,000[32]. - The group's cash and cash equivalents as of June 30, 2025, were RMB 424,849,000, down from RMB 1,774,358,000 as of December 31, 2024[64]. - The net current assets decreased by RMB 247,884,000 or 11.4%, from RMB 2,169,969,000 as of December 31, 2024, to RMB 1,922,085,000 as of June 30, 2025[66]. - The total bank borrowings amounted to RMB 1,655,064,000, all at fixed interest rates, due for repayment by June 30, 2026[73]. - The financing activities generated a net cash flow of RMB 617,723,000, an increase from RMB 413,594,000 in 2024, primarily due to new bank borrowings[94]. - The net cash flow from operating activities was RMB (1,869,376) thousand, a significant decrease compared to RMB 3,737 thousand for the same period in 2024[93]. - The net cash flow used in investing activities was RMB (91,360) thousand, compared to RMB (55,796) thousand in the previous year, indicating increased investment outflows[93]. Expenses and Cost Management - Selling and distribution expenses increased by 17.0% to RMB 70,314,000 from RMB 60,090,000 for the six months ended June 30, 2024, mainly due to increased technical service fees paid to a potential partner[57]. - Administrative expenses rose by 23.0% to RMB 93,652,000 from RMB 76,169,000 for the same period in 2024, primarily due to increased labor costs[59]. - Other expenses increased significantly by 1,744.4% to RMB 24,899,000 from RMB 1,350,000 for the six months ended June 30, 2024, mainly due to increased foreign exchange losses[60]. - Financing costs increased by 92.7% to RMB 22,414,000 from RMB 11,629,000 for the same period in 2024, primarily due to an increase in average bank borrowings[61]. Shareholder and Equity Information - The company issued 270,918,016 new shares at a placement price of HKD 0.7 per share, raising approximately RMB 173,142,000, which contributed to an increase in share capital[133]. - The company repurchased and cancelled shares amounting to RMB (8,117) thousand during the period[93]. - The total equity attributable to the company's owners was RMB 3,466,972,000 as of June 30, 2025, down from RMB 3,714,618,000 as of December 31, 2024[65]. - The company has not declared any interim dividends for the reporting period, with no dividends declared for the six months ending June 30, 2024[185]. Strategic Initiatives and Future Plans - The company has established a global strategic cooperation framework with HashKey Group to optimize trading costs and strengthen asset management mechanisms in the digital asset financial services sector[24]. - The company plans to adopt a regular investment strategy to continuously increase its Ethereum holdings[25]. - The board proposed to seek shareholder approval for potential cryptocurrency purchases not exceeding HKD 3 billion over the next 36 months[147]. - The company is pursuing a dual primary listing on the NASDAQ through the issuance of American Depositary Shares[187]. - The company has entered into a strategic cooperation framework agreement with HashKey Group to enhance digital asset services and has purchased 5,190 ETH at USD 3,661 each[190]. Employee and Management Compensation - The total employee compensation expenses for the reporting period were RMB 75,403,000, an increase from RMB 66,402,000 for the six months ended June 30, 2024[80]. - Total compensation for key management personnel increased to RMB 10,248,000 for the six months ended June 30, 2025, compared to RMB 8,135,000 for the same period in 2024, reflecting a growth of about 26%[138]. - The company recorded a significant increase in short-term employee benefits to RMB 9,531,000 for the six months ended June 30, 2025, compared to RMB 7,555,000 for the same period in 2024, marking an increase of about 25.9%[138]. Stock Options and Incentive Plans - The stock option plan aims to attract and retain talent, providing additional incentives to eligible participants[158]. - The number of stock options granted to any eligible participant within a twelve-month period is limited to 1% of the total issued shares[160]. - The company has adopted a new share incentive plan effective after the reporting period, with details provided in a circular dated June 6, 2025[177]. - The maximum number of shares that can be granted under the share incentive plan is limited to 10% of the company's issued share capital, with individual grants not exceeding 1%[170]. - The company has not granted any shares under the share incentive plan during the reporting period[177].